Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alternative complement pathway in hypocomplementemic/normal C1s-C1 inhibitor complex patients with SLE.

R A Levy1, T Qamar, M D Lockshin

  • 1Hospital for Special Surgery, Cornell University Medical Center, New York, New York.

Clinical and Experimental Rheumatology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of different classes of lupus nephritis on maternal and fetal outcomes: a cohort study of 147 pregnancies.

Lupus·2019
Same author

Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study.

BJOG : an international journal of obstetrics and gynaecology·2018
Same author

Longitudinal evaluation of diffusion tensor imaging and cognition in systemic lupus erythematosus.

Lupus·2018
Same author

Gestational outcomes in patients with neuropsychiatric systemic lupus erythematosus.

Lupus·2017
Same author

Lupus and the brain: neuropsychiatric aspects in systemic lupus erythematosus.

Lupus·2017
Same author

Ventilation distribution and small airway function in patients with systemic sclerosis.

Revista portuguesa de pneumologia·2017
Same journal

The expanded cardiovascular risk prediction score as a cardiovascular mortality predictor in rheumatoid arthritis.

Clinical and experimental rheumatology·2026
Same journal

Rising overweight and obesity in Swiss psoriatic arthritis patients, 2007-2022: a nationwide registry-population comparison.

Clinical and experimental rheumatology·2026
Same journal

Clinical features and gastrointestinal bleeding risk factors in IgA vasculitis patients: a retrospective study in a large volume centre.

Clinical and experimental rheumatology·2026
Same journal

Reply to the comment on: The microbiota in axial spondyloarthritis: what have we learned from Mendelian randomisation studies?

Clinical and experimental rheumatology·2026
Same journal

Comprehensive evaluation of bone structural and microarchitectural changes in rheumatoid arthritis treated with baricitinib using HR-pQCT, imaging, and biomarker analyses.

Clinical and experimental rheumatology·2026
Same journal

Tracking interstitial lung disease in systemic sclerosis: integrating lung magnetic resonance imaging into a clinically oriented multimodal follow-up strategy.

Clinical and experimental rheumatology·2026
See all related articles

Alternative complement pathway activation does not explain low complement levels in systemic lupus erythematosus patients with normal C1s-C1 inhibitor complex. Further research is needed to understand hypocomplementemia in these patients.

Area of Science:

  • Immunology
  • Complement System Biology

Background:

  • Systemic lupus erythematosus (SLE) is often associated with hypocomplementemia.
  • The role of the alternative complement pathway in SLE hypocomplementemia, particularly in patients with normal C1s-C1 inhibitor complex, remains unclear.

Purpose of the Study:

  • To investigate whether alternative complement pathway activation contributes to hypocomplementemia in SLE patients.
  • To examine the relationship between classical pathway activation (indicated by elevated C1s-C1 inhibitor complex) and alternative pathway markers in hypocomplementemic SLE patients.

Main Methods:

  • Analysis of hypocomplementemic SLE sera for hemolytic complement (CH50alt), factor B, and Ba fragment levels.
  • Comparison of complement component levels (CH50cl, C3, C4) between patients with normal and elevated C1s-C1 inhibitor complex.

Related Experiment Videos

  • Assessment of potential differences between pregnant and non-pregnant patients.

    • Main Results:

    • Sera with normal and elevated C1s-C1 inhibitor complex showed similar levels of CH50cl, C3, and C4.
    • Little evidence of significant alternative complement pathway activation was observed in either patient group.
    • Patients with classical pathway activation exhibited slightly lower CH50alt and slightly higher factor B and Ba levels compared to those with normal C1s-C1 inhibitor complex.

    Conclusions:

    • Alternative complement pathway activation does not account for hypocomplementemia in SLE patients with normal C1s-C1 inhibitor complex.
    • The findings suggest that the alternative pathway is not the primary driver of low complement levels in this specific SLE patient cohort.